KR970706004A - 호르몬 약물 및 에스트로겐 결핍을 치유하기 위한 그의 용도(novel hormonal medicaments and use thereof for correcting oestrogen deficiencies) - Google Patents

호르몬 약물 및 에스트로겐 결핍을 치유하기 위한 그의 용도(novel hormonal medicaments and use thereof for correcting oestrogen deficiencies)

Info

Publication number
KR970706004A
KR970706004A KR1019970702125A KR19970702125A KR970706004A KR 970706004 A KR970706004 A KR 970706004A KR 1019970702125 A KR1019970702125 A KR 1019970702125A KR 19970702125 A KR19970702125 A KR 19970702125A KR 970706004 A KR970706004 A KR 970706004A
Authority
KR
South Korea
Prior art keywords
estrogen
progestogen
present
estradiol
amount
Prior art date
Application number
KR1019970702125A
Other languages
English (en)
Other versions
KR100450649B1 (ko
Inventor
랑꿰땡 미셸
빠리 자끄
또마 장-루이
Original Assignee
프랑스와 루게쥐농
라보라뜨와르 떼라멕스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9481610&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR970706004(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 프랑스와 루게쥐농, 라보라뜨와르 떼라멕스 filed Critical 프랑스와 루게쥐농
Publication of KR970706004A publication Critical patent/KR970706004A/ko
Application granted granted Critical
Publication of KR100450649B1 publication Critical patent/KR100450649B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

본 발명은 화학 요법의 분야에 관한 것이다.
보다 상세하게, 본 발명은 3종의 연속으로 투여되는 에스트로-프로게스토겐 조합물에 관한 것으로, 에스트로겐을 함유하는 투여 단위체, 에스트로겐 및 프로게스토겐의 조합물을 함유하는 투여 단위체 및 부형제만을 함유하는 투여 단위체로 이루어짐을 특징으로 한다.
이러한 3종 연속 투여 형태는 폐경 또는 조기폐경과 관련된 에스트로겐감퇴증에 의한 기능적 장애를 보충하는데 사용된다.

Description

호르몬 약물 및 에스트로겐 결핍을 치유하기 위한 그의 용도(NOVEL HORMONAL MEDICAMENTS AND USE THEREOF FOR CORRECTING OESTROGEN DEFICIENCIES)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (11)

  1. 에스트로겐, 에스트로겐/프로게스토겐 조합물 및 마지막에 플라세보를 1개월에 거쳐 경구적으로 투여함을 포함하여 폐경기 여성의 에스트로겐 결핍을 치료하기 위 에스트로-프로게스토겐 혼합물의 용도.
  2. 제1항에 있어서, 에스트로겐이 17β-에스트라디올임을 특징으로 하는 혼합물의 용도
  3. 제1항에 있어서, 프로게스토겐이 노메게스트롤 아세테이트임을 특징으로 하는 혼합물의 용도.
  4. 제1항 또는 제2항에 있어서, 에스트로겐을 단독으로 10일 동안 17β-에스트라디올 정제의 형태로 투여함을 특징으로 하는 에스트로-프로게스토겐 혼합물의 용도.
  5. 제1항 내지 3항 중 어느 한 항에 있어서, 에스트로겐 및 프로게스토겐의 조합물을 14일 동안 연속적으로 투여함을 특징으로 하는 에스트로-프로게스토겐 혼합물의 용도.
  6. 제1항에 있어서, 플라세보 정제를 6일 동안 연속적으로 투여함을 특징으로 하는 에스트로-프로게스토겐 혼합물의 용도.
  7. 17β-에스트라디올이 단위 투여량당 1내지 3㎎의 분량으로 존재함을 특징으로 하는 제1항에 따른 에스트로겐 조성물.
  8. 17β-에스트라디올이 단위 투여량당 1내지 3㎎의 분량으로 존재하고, 노메게스트롤 아세테이트이 1.5 내지 6㎎의 분량으로 존재함을 특징으로 하는 제1항에 따른 에스트로-프로게스토겐 조성물.
  9. 제7항에 있어서, 17β-에스트라디올이 단위 투여량당 1내지 2㎎, 바람직하게는 1.5㎎의 분량으로 존재함을 특징으로 하는 제1항에 따른 조성물.
  10. 제7항 또는 제8항에 있어서, 17β-에스트라디올이 단위 투여량당 1내지 2㎎의 분량으로 존재하고, 노메게스트롤 아세테이트이 2.5 내지 5㎎의 분량으로 존재함을 특징으로 하는 제1항에 따른 에스트로-프로게스토겐 조성물.
  11. 제7항에 따른 에스트로겐 조성물을 제조하는 방법으로서, 친수성 결합제중에 에스트라디올을 분산시킨후, 불활성 희석제 및 압축 결합제를 부가하고, 매스를 과립화시키고, 건조시키고, 분쇄시키고, 임의로 이혼합물에 노메게스트롤 아세테이트 및 압축 첨가제를 부가하여 17β-에스트라디올 및 노메게스트롤 아세테이트를 함유하는 정제를 제조하는 것을 특징으로 하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019970702125A 1995-08-01 1996-07-29 호르몬약물및에스트로겐결핍을치유하기위한그의용도 KR100450649B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR95/09364 1995-08-01
FR9509364A FR2737411B1 (fr) 1995-08-01 1995-08-01 Nouveaux medicaments hormonaux et leur utilisation pour la correction des carences estrogeniques

Publications (2)

Publication Number Publication Date
KR970706004A true KR970706004A (ko) 1997-11-03
KR100450649B1 KR100450649B1 (ko) 2004-11-16

Family

ID=9481610

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019970702125A KR100450649B1 (ko) 1995-08-01 1996-07-29 호르몬약물및에스트로겐결핍을치유하기위한그의용도

Country Status (31)

Country Link
US (1) US5891867A (ko)
EP (1) EP0783310B1 (ko)
JP (1) JPH10507207A (ko)
KR (1) KR100450649B1 (ko)
CN (1) CN1138547C (ko)
AP (1) AP829A (ko)
AR (1) AR004502A1 (ko)
AT (1) ATE225659T1 (ko)
AU (1) AU722355B2 (ko)
BR (1) BR9606549A (ko)
CA (1) CA2201368C (ko)
CZ (1) CZ289706B6 (ko)
DE (1) DE69624214T2 (ko)
DK (1) DK0783310T3 (ko)
DZ (1) DZ2078A1 (ko)
ES (1) ES2184880T3 (ko)
FR (1) FR2737411B1 (ko)
HK (1) HK1005227A1 (ko)
HU (1) HU229843B1 (ko)
IL (1) IL120558A (ko)
MA (1) MA23946A1 (ko)
MX (1) MX9702381A (ko)
MY (1) MY117307A (ko)
NO (1) NO312996B1 (ko)
OA (1) OA10411A (ko)
PT (1) PT783310E (ko)
RU (1) RU2188641C2 (ko)
TN (1) TNSN96101A1 (ko)
TW (1) TW473390B (ko)
WO (1) WO1997004784A1 (ko)
ZA (1) ZA966545B (ko)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001030355A1 (fr) * 1999-10-25 2001-05-03 Laboratoire Theramex Medicament contraceptif a base d'un progestatif et d'un estrogene et son mode de preparation
FR2754179B1 (fr) * 1996-10-08 1998-12-24 Theramex Nouvelle composition hormononale et son utilisation
US6787531B1 (en) * 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
WO2001030356A1 (fr) 1999-10-25 2001-05-03 Laboratoire Theramex Composition hormonale a base d'un progestatif et d'un estrogene et son utilisation
US20020132801A1 (en) * 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
FR2814074B1 (fr) * 2000-09-15 2003-03-07 Theramex Nouvelles compositions estro-progestatives topiques a effet systemique
US20020151732A1 (en) * 2001-01-05 2002-10-17 Claes Ohlsson Estrogen receptors
US20030004145A1 (en) * 2001-05-16 2003-01-02 Leonard Thomas W. Treatment of conditions relating to hormone deficiencies by administration of progestins
HU230759B1 (hu) * 2001-12-05 2018-03-28 Teva Women's Health, Inc. Teherbeesés megakadályozására és menstruációs tünetek enyhítésére vagy kiküszöbölésére alkalmas orális készítmények
US7008979B2 (en) * 2002-04-30 2006-03-07 Hydromer, Inc. Coating composition for multiple hydrophilic applications
NZ585546A (en) * 2003-07-16 2011-10-28 Teva Womens Health Inc Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration
US20070111975A1 (en) 2004-10-07 2007-05-17 Duramed Pharmaceuticals, Inc. Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens
US8022053B2 (en) * 2004-11-02 2011-09-20 Bayer Schering Pharma Aktiengesellschaft Oral solid dosage forms containing a low dose of estradiol
US20080242650A1 (en) * 2007-03-26 2008-10-02 Jean-Louis Thomas Oral contraceptive regimen

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4390531A (en) * 1981-08-10 1983-06-28 Syntex Pharmaceuticals International Ltd. Method of contraception using peak progestogen dosage
US4826831A (en) * 1983-08-05 1989-05-02 Pre Jay Holdings Limited Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens
FR2695826B1 (fr) * 1992-09-21 1995-01-06 Theramex Nouvelles compositions pharmaceutiques à base de dérivés de nomégestrol et leurs procédés d'obtention.

Also Published As

Publication number Publication date
NO971449D0 (no) 1997-03-26
ZA966545B (en) 1997-05-08
TW473390B (en) 2002-01-21
FR2737411A1 (fr) 1997-02-07
CN1138547C (zh) 2004-02-18
JPH10507207A (ja) 1998-07-14
HUP9900612A2 (hu) 1999-07-28
AP9700979A0 (en) 1997-07-31
OA10411A (fr) 2001-12-06
HUP9900612A3 (en) 1999-11-29
CA2201368C (fr) 2010-12-07
DK0783310T3 (da) 2003-02-10
CA2201368A1 (fr) 1997-02-13
EP0783310B1 (fr) 2002-10-09
HK1005227A1 (en) 1998-12-31
MY117307A (en) 2004-06-30
AU6367496A (en) 1997-02-26
AP829A (en) 2000-05-03
ES2184880T3 (es) 2003-04-16
CZ96797A3 (cs) 1998-08-12
RU2188641C2 (ru) 2002-09-10
IL120558A (en) 2002-09-12
CZ289706B6 (cs) 2002-03-13
DZ2078A1 (fr) 2002-10-22
IL120558A0 (en) 1997-07-13
NO312996B1 (no) 2002-07-29
HU229843B1 (en) 2014-09-29
WO1997004784A1 (fr) 1997-02-13
DE69624214T2 (de) 2003-07-10
NO971449L (no) 1997-05-30
TNSN96101A1 (fr) 2005-03-15
CN1167438A (zh) 1997-12-10
ATE225659T1 (de) 2002-10-15
FR2737411B1 (fr) 1997-10-17
EP0783310A1 (fr) 1997-07-16
DE69624214D1 (de) 2002-11-14
BR9606549A (pt) 1998-06-23
PT783310E (pt) 2003-02-28
US5891867A (en) 1999-04-06
KR100450649B1 (ko) 2004-11-16
AR004502A1 (es) 1998-12-16
AU722355B2 (en) 2000-07-27
MA23946A1 (fr) 1997-04-01
MX9702381A (es) 1998-02-28

Similar Documents

Publication Publication Date Title
US3568828A (en) Modified sequential oral contraceptive
FI98985C (fi) Ehkäisyvalmiste
US5521166A (en) Antiprogestin cyclophasic hormonal regimen
ES2356408T3 (es) Medicamento que incluye al menos un gestágeno.
KR900701277A (ko) 피임 시스템 및 방법
RU2001129160A (ru) Прерывистая гормонозаместительная терапия низкими дозами эстрогена
EP1689411B1 (en) Graduated estrogen contraceptive
CA2267743A1 (en) Low dose estrogen interrupted hormone replacement therapy
KR970706004A (ko) 호르몬 약물 및 에스트로겐 결핍을 치유하기 위한 그의 용도(novel hormonal medicaments and use thereof for correcting oestrogen deficiencies)
ATE216241T1 (de) Sehr niedrigdosiertes orales kontrazeptiv mit weniger menstruationsblutungen und verzögerter wirkung
KR920011514A (ko) 프로게스토겐만을 함유하는 피임제
JPH04290828A (ja) 低エストロゲン経口避妊薬
RU96115196A (ru) Состав для контрацепции
JP2000514785A (ja) プロゲストゲン―抗プロゲストゲン処方
BG100940A (en) Combined hormonal contraception pharmaceutical preparation
RU96119957A (ru) Фармацевтический комбинированный препарат для гормональной контрацепции
AR016502A1 (es) Uso de sulfamatos estrogenos biogenicos en una terapia de reemplazo de hormonas.
NO327588B1 (no) Farmasoytisk sammensetning og preparat omfattende etinylostradiol og drospirenon for anvendelse som antikonsepsjonsmiddel
EP0300523B1 (en) Pharmaceutical dosage unit for the prevention or treatment of climacteric complaints
ES2590914T3 (es) Preparación hormonal que contiene una combinación de etinilestradiol y acetato de clormadinona
RU97108279A (ru) Новые гормональные лекарственные препараты и их применение для коррекции эстрогенной недостаточности
NZ307178A (en) Medicament for contraception; contains two, separately packed, sequential hormonal components
US3230142A (en) Oral contraceptive compositions and methods
JP2942560B2 (ja) エストロゲン欠乏症治療用組成物
RU2394579C2 (ru) Применение комбинации из этинилэстрадиола и ацетата хлормадинона для приготовления лекарственного средства

Legal Events

Date Code Title Description
A201 Request for examination
AMND Amendment
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
J201 Request for trial against refusal decision
AMND Amendment
B90T Transfer of trial file for re-examination
B701 Decision to grant
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20120910

Year of fee payment: 9

FPAY Annual fee payment

Payment date: 20130912

Year of fee payment: 10

FPAY Annual fee payment

Payment date: 20140911

Year of fee payment: 11

FPAY Annual fee payment

Payment date: 20150911

Year of fee payment: 12

EXPY Expiration of term